FDA & Government News

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

Share

In a phase 3b trial, ixekizumab combined with tirzepatide demonstrated superior efficacy in achieving both complete skin clearance and significant weight loss in patients with moderate-to-severe plaque psoriasis and obesity. The TOGETHER-PsO trial enrolled 274 participants and showed that 27% of those receiving the combination therapy reached the primary endpoint, compared to just 6% with ixekizumab alone. The safety profile remained consistent across treatments with mild to moderate adverse effects. Detailed results are forthcoming.

Original Source(s)

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.

  • by Kathryn Wighton

  • February 18, 2026

  • 3 min

Related Content

Does Air Pollution Affect Skin Health?

Large systematic review finds consistent associations across conditions but highlights low certainty driven by bias and study heterogeneity.

Novel Gene Variants May Be Predisposing Factor for Generalized Pustular Psoriasis

Researchers may have uncovered genetic factors linked to the development of generalized pustular psoriasis.

Patient Insights on HRQOL in Chronic GVHD

Explore how cutaneous graft-versus-host disease impacts patients’ quality of life across physical, psychological, and social domains.